drugset

drugset / Trial / NCT04318093

Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure

NCT04318093 ↗

Phase 2 Completed 25 enrolled Bristol-Myers Squibb

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to assess the safety of BMS-986259 in stable participants hospitalized for acute decompensated heart failure.

Timeline

Start: 2020-11-06
Primary completion: 2021-07-19
Completion: 2021-07-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-986259	Unknown	—	—

Indications